Candriam S.C.A. Immunome Inc. Transaction History
Candriam S.C.A.
- $18.4 Billion
- Q3 2025
A detailed history of Candriam S.C.A. transactions in Immunome Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 859,527 shares of IMNM stock, worth $14.7 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
859,527
Previous 318,086
170.22%
Holding current value
$14.7 Million
Previous $2.96 Million
236.75%
% of portfolio
0.05%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding IMNM
# of Institutions
166Shares Held
71.5MCall Options Held
325KPut Options Held
4.31M-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.42MShares$144 Million0.06% of portfolio
-
Redmile Group, LLC San Francisco, CA5.02MShares$86.1 Million6.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$83.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.82MShares$82.7 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.08MShares$69.9 Million3.55% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $208M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...